Abstracts tagged "statin"

Abstract Number: 0283 • ACR Convergence 2021
Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
SAMAR ABOULENAIN¹, Khaled Deeb², Mohamed Abdul Qader¹ and Can Jones¹, ¹University of Miami Miller School, West Palm Beach, FL, ²West Palm Beach VA Medical Center, West Palm Beach, FL
Background/Purpose: Cardiovascular (CV) disease is the leading cause of death in patients with rheumatoid arthritis (RA) and is estimated to be responsible for 29%-32% of…
Abstract Number: 1366 • ACR Convergence 2021
The Use of Lipid-Lowering Agents in Systemic Sclerosis: Is There a Relationship with Prevalence of Digital Ulcers and Overall Survival?
Olivia Sallis¹, Dylan Hansen², Kathleen Morrisroe³, Wendy Stevens³, Mandana Nikpour⁴ and Susanna Proudman⁵, ¹Royal Adelaide Hospital, Adelaide, Australia, ²St. Vincent’s Hospital Melbourne, Victoria, Australia, Adelaide, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁵University of Adelaide, Medindie, Australia
Background/Purpose: Digital ulcers (DU) are common in systemic sclerosis (SSc). Vasodilator therapies have limited benefit in prevention and promoting healing. Lipid-lowering agents (LLAs) such as…
Abstract Number: 445 • 2019 ACR/ARP Annual Meeting
What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis
Elena Myasoedova¹, Paras Karmacharya ¹, Ali Duarte Garcia ¹, John Davis ¹, M.Hassan Murad ¹ and Cynthia Crowson ², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: The anti-inflammatory and immune-modulating effects of statins suggest that these drugs may influence the risk of developing autoimmune diseases, such as rheumatoid arthritis (RA). …
Abstract Number: 955 • 2019 ACR/ARP Annual Meeting
Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study
Tom Hahn ¹, Eric Sayre ², Maria Victoria Goycochea-Robles ³ and Diane Lacaille⁴, ¹Department of Medicine, University of British Columbia, Vancouver, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Unidad de Investigación en Epidemiologia HGR 1, Mexican Institute of Social Security -, Mexico City, Mexico, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Cardiovascular diseases (CVD) are increased in RA and lead to premature mortality. Statins are effective at preventing incidence of, and mortality from, CVD; yet,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].